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Abstract
Gene expression is potently regulated through the action of microRNAs (miRNAs). Here, we present evidence of a miRNA
regulating Hakai protein. Hakai was discovered as an E3 ubiquitin-ligase that mediates the posttranslational downregulation
of E-cadherin, a major component of adherens junctions in epithelial cells and a potent tumour suppressor. Recent data
have provided evidence that Hakai affects cell proliferation in an E-cadherin-independent manner, thus revealing a role for
Hakai in the early stages of tumour progression. Furthermore, Hakai is highly up-regulated in human colon
adenocarcinomas compared to normal tissues. However, the molecular mechanisms that regulate Hakai abundance are
unknown. We identified two putative sites of miR-203 interaction on the Hakai mRNA, in its 39-untranslated region (UTR). In
several human carcinoma cell lines tested, overexpression of a miR-203 precursor (Pre-miR-203) reduced Hakai abundance,
while inhibiting miR-203 by using an antisense RNA (Anti-miR-203) elevated Hakai levels. The repressive influence of miR-
203 on the Hakai 39-UTR was confirmed using heterologous reporter constructs. In keeping with Hakai’s proliferative
influence, Anti-miR-203 significantly increased cell number and BrdU incorporation, while Pre-miR-203 reduced these
parameters. Importantly, the growth-promoting effects of anti-miR-203 required the presence of Hakai, because
downregulation of Hakai by siRNA suppressed its proliferative action. Finally, in situ hybridization showed that miR-203
expression is attenuated in colon tumour tissues compared to normal colon tissues, suggesting that miR-203 could be a
potential new prognostic marker and therapeutic target to explore in colon cancer. In conclusion, our findings reveal, for
the first time, a post-transcriptional regulator of Hakai expression. Furthermore, by lowering Hakai abundance, miR-203 also
reduces Hakai-regulated-cell division.
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Introduction
Carcinoma arises from epithelial cells on which cancer cells start
an uncontrolled proliferation and, in order to metastasize, some
cells detach from the primary tumour, migrate and invade through
tissues. One hallmark of metastasis is the disruption of epithelial
integrity and loss of intercellular adhesion. Downregulation of
cell–cell adhesion is characterized by the loss of E-cadherin, the
best protein characterized and prototype member of the classical
cadherins in epithelial cells, which are potent tumour suppressors
in epithelial cells [1]. Epithelial tumours often lose E-cadherin
partially or completely as they progress toward malignancy [2,3].
Given the great impact of E-cadherin in cancer, the mechanisms
that control E-cadherin inactivation in human cancers have been
extensively studied [4,5]. In 2002, the protein Hakai was identified
as the first post-translational regulator of E-cadherin stability.
Since then, many studies on the emerging biological functions of
Hakai have underscored its influence on tumour progression and
disease [6]. Hakai is an E3 ubiquitin-ligase that mediates the
ubiquitination of E-cadherin protein upon Src activation, in turn
mediating its lysosomal degradation [6–9]. Since then, novel
proteins substrates for Hakai have been identified, such as
Cortactin, a protein critically involved in the reorganization of
actin cytoskeleton in cell protrusions, and DOK1, which binds to
p120-rasGAP, a potent inhibitor of Ras oncogene [10]. Besides
influencing cell adhesion, Hakai has also been implicated in
controlling cell migration and embryogenesis [11–13], and it can
control cell proliferation in an E-cadherin-independent manner,
further supporting a role for Hakai in early stages of tumorigenesis
[14,15]. Accordingly, Hakai is highly up-regulated in human colon
adenocarcinomas compared to normal tissues. Underscoring the
interest exploiting Hakai as a therapeutic target, its molecular
structure was recently solved [10]. However, to-date, no regulators
of Hakai expression have been described.
Over the last decade, microRNAs (miRNAs) have emerged as
key players in carcinogenesis. Aberrant expression of miRNAs has
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been demonstrated to play a critical role in the initiation and
progression of several cancers [16]. miRNAs are small (,22-nt),
single-stranded, non-coding RNAs that play a key role in
development and diseases through post-transcriptional regulation
of gene expression [17–19]. Synthesized as longer primary
transcripts by RNA polymerase II, pri-miRNAs are processed by
the nuclear RNase Drosha into 70-nt hairpin precursor miRNAs
(pre-miRNAs). Following Exportin 5-mediated transport to the
cytoplasm, pre-miRNAs are further processed by the RNase
Dicer, giving rise to mature miRNAs that assemble with members
of the argonaute (Ago) protein family into the RNA-induced
silencing complex (RISC). The miRNA then directs the complex
to target mRNAs typically reducing their translation and/or
stability [20–24]. miRNAs generally bind with partial comple-
mentary one or more sites in the target 39-untranslated region
(39UTR) of the target mRNA [25].
Here, we describe the identification of miRNA-203 as a
negative regulator of Hakai expression. Our results demonstrate
that miR-203 targets Hakai mRNA by binding to the 39UTR of
the Hakai mRNA, lowering Hakai expression and decreasing cell
proliferation. Furthermore, immunohistochemcal analysis re-
vealed that Hakai protein levels were higher in paired colon
cancer tissues compared to adjacent healthy colon tissues and an
inverse correlation was found for miR-203 levels by in situ
hybridization, further suggesting a tumour suppressor role for
miR-203 in colon cancer.
Materials and Methods
Antibodies and Materials
The rabbit polyclonal anti-Hakai antibody (Hakai-2498) and
the pEGFP-Hakai construct were kindly provided by Dr. Yasuyuki
Fujita [14]. Antibody anti-AKT2 was from Santa Cruz Biotech-
nology (Santa Cruz, CA). Anti-GFP was from Abcam (Cambridge,
UK), anti-a-tubulin antibody was from Sigma-Aldrich (St Louis,
MO), anti-BrdU antibody was from Calbiochem (Darmstadt,
Germany), HRP-rabbit and mouse polyclonal antibodies were
from GE Healthcare (UK) and E-cadherin antibody was from
Invitrogen. All antibodies were used at a dilution of 1:1000 for
Western blot analysis, except the anti-GFP antibody, which was
used at a dilution of 1:5000. Cells were transiently transfected with
small RNAs and/or plasmids using Lipofectamine 2000 (Invitro-
gen, UK), following the manufacturer’s instructions. At 48 h after
transfection, cells were processed for RNA and protein analysis.
The pre-miRNA and anti-miRNA for human miR-203 and miR-
21, and scrambled negative controls (Ctrl) miRNA were obtained
from Life Technologies (Applied Biosystems, UK) and used at final
concentration of 3 mM. Oligos used for Hakai siRNA were Hakai-
1 (CTCGATCGGTCAGTCAGGAAA) and Hakai-2 (CACCGC-
GAACTCAAAGAACTA) as previously described [14] and as a
negative control (Ctrl), we used scrambled siRNA from Sigma-
Aldrich (St Louis, MO).
Cell Lines and Human Tissue Samples
Human cell lines HeLa (cervical carcinoma), HEK-293
(embryonic kidney cells), HT29 (colorectal adenocarcinoma),
SW480 (colon adenocarcinoma), SW620 (colon adenocarcinoma)
and A549 (lung adenocarcinoma) were obtained from American
Type Culture Collections (Manassas, VA). Cells were cultured in
DMEM or RPMI containing penicillin/streptomycin and 10%
FCS at 37uC and ambient air supplemented with 5% CO2.
Formalin-fixed, paraffin-embedded (FFPE) colon cancer tissues
were obtained from the pathological anatomy department from
the Complejo Hospitalario Universitario A Coruña (CHUAC, A
Coruña), under informed consent from all the patients and
research investigation was approved by the institutional research
ethics committee. The data were analyzed anonymously. All slides
were reviewed by a pathologist expert for the identification of the
tumour region as well as adjacent normal colon epithelium.
RNA Analysis and Protein Analysis
Total RNA was isolated using TriPure Reagent (Roche,
Germany) according to the manufacturers instruction. After
isolation, the obtained pellet was washed by following an
alternative protocol described for small RNAs in RiboPure (Life
Technologies, UK). The quality and quantity of the obtained
RNA was determined by using Nanodrop ND-spectrophotometer
(Thermo Fisher Scientific, MA, USA). After reverse transcription
(RT) using random hexamers and SuperScript first-strand
Synthesis System for RT-PCR (Invitrogen, UK), real-time
quantitative PCR analysis was performed using gene-specific
primers 59-CGCAGACGAATTCCTATAAAGC -39 and 59-
CCTTCTTCATCACCAGGTGG -39 for human Hakai; and
59-TGACCTTGATTTATTTTGCATACC-39 and 59-CGAG-
CAAGACGTTCAGTCCT-39 for HPRT. PCR was performed
by using Light Cycler 480 SYBR Green I Master (Roche,
Germany).
For miRNA analysis, 25 ng of the extracted RNA was amplified
and detected by using the Taqman microRNA detection assay
following the manufacturer’s procedure (Applied Biosystems, UK).
Probes for miR-203 and miR-21 (Applied Biosystems, UK) were
used and U6 snRNA probe was employed for normalization. The
amplification and quantification of cDNA was carried out by using
a LightCycler 480 real-time lightcycler (Roche, Germany).
For protein extraction, cell lysates (30 mg of proteins) were
obtained by using 1% Triton X-100 lysis buffer (20 mM Tris/HCl
pH 7.5, 150 mM NaCl and 1% Triton X-100) containing 5 mg/
ml leupeptin, 50 mM PMSF and 7.2 units of trypsin inhibitor
aprotinin and western blotting was performed as we described
previously [26].
EGFP Reporters Containing 39-UTR Hakai mRNA
Sequence
To construct the EGFP reporter plasmid containing 39UTR or
Hakai mRNA we used the following PCR primers: 59-
GGTTCCCTCGAGCTAAGGAAGAGTACCTCTTATC-
GAGG-39 and 59-GGTTCCGAATTCCCTCAACATTT-
CAGTGCC-39 and the resulting PCR products were ligated into
pEGFP (Clontech, California, USA). The reporter vector and the
pEGFP alone were cotransfected with the indicated miRNAs as
described above. Cells were fixed with 3.7% paraformaldehyde/
PBS for 15 min. Immunofluorescence images were analyzed by
epifluorescence microscopy. Phase contrast images were acquired
using a Nikon Eclipse-Ti microscope.
Proliferation Assay and Flow Cytometry Analysis
For quantification of cell numbers, 2.56104 cells were plated
per well into a 6-well plate; 48 h after transfection, cells were
counted using hemocytometer. For colorimetric analysis,
16104 cells were plated per well into a 96-well plate and after
48 h of transfection they were treated with 10 mM BrdU for 2 h.
BrdU incorporation into newly synthesized DNA was measured
using a cell proliferation colorimetric immunoassay kit (Calbio-
chem, Germany) according to the manufacturer’s instructions. For
the flow cytometry analysis, cells were trypsinized, washed with
PBS containing 1 mM EDTA, and fixed following incubation in
PBS containing 100 mg/ml of RNase and 50 mg/ml propidium
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iodide (Sigma), DNA was analyzed by FACSscan flow cytometer
(Becton Dickinson, USA). Data were acquired and analyzed by
Cell Quest Program (Becton Dickinson, USA).
Immunohistochemistry and in situ Hybridization
For immunohistochemistry, tissue sections were deparaffinized
and antigen retrieval was performed in citrate buffer (Dako REAL,
Denmark) by heating the samples (2100 Retriever; PickCell
Laboratories). After 20 minutes at room temperature, the
endogenous peroxidase activity was inhibited with peroxidase-
blocking solution (Dako REAL, Denmark). Primary antibodies
were incubated overnight at 4uC. Finally, detection was carried
out by using Dako REAL EnVision Detection system according to
the manufacturer’s instructions. Nuclei were slightly counter-
stained with Gill’s hematoxylin. Calibration and quantification of
the images was performed with AnalySISD 5.0 software (Olympus
Biosystems, Hamburg, Germany).
In situ hybridization was performed using the instruction of v2.0
miRCURY LNA microRNA ISH Optimization kit for FFPE
(Exiqon, Denmark), using double DIG-labeled mercury LNAmi-
croRNA Detection probes. It was used miR-203 probe and LNA
U6 snRNA for detection of control probe and scramble
microRNA probe. All probes were used at final concentration of
0.25 nM except for U6, which was used at 0.005 nM.
Target Prediction
miRNA target prediction was carried out by using TargetScan
(release 5.1; http://www.targetscan.org/).
Statistical Analysis
Unless indicated, all experiments were analyzed by using
Students t-test to evaluate differences between treatments at the
indicated significance levels. For quantitative image analysis of
immunohistochemical staining, the Mann-Whitney U-test was
employed. SPSS statistics 20 (IBM, New York, US) was used for
data management in the statistical analyses.
Results
miR-203 Regulates Hakai Protein Levels
In recent years, the refinement of miRNA-mRNA prediction
algorithms, along with improved knowledge of miRNA target
recognition and increasing availability of relevant data sets have
greatly improved our ability to anticipate regulatory miR-
NA:mRNA interactions. Data driven algorithms rely on important
discriminative features learned from data using sophisticated
models [27–29]. miR-203 was predicted to bind to Hakai mRNA
at two sites within 39-UTR, positions 1965 to 1977 and from 2172
to 2198 (Targetscan) (Figure 1A). The effect of miR-203 on Hakai
expression was tested in HeLa cells, which did not express E-
cadherin, as shown in Figure S1 and previously published [30]. To
elevate miR-203 levels, the precursor miR-203 transcript (pre-
miR-203) was transfected and after 48 h after transfection, Hakai
expression was analyzed by reverse transcription followed by
quantitative real-time PCR (RT-qPCR) and Western blotting. The
increased level of miR-203 was confirmed in cells transfected with
pre-miR-203, compared to cell transfected with scrambled control
miRNA (Ctrl) and to un-transfected cells (Figure 1B). Under these
conditions, Hakai mRNA levels were only modestly lower
(Figure 1C), while Hakai protein levels were strongly reduced in
the pre-miR-203 group compared to the scrambled Ctrl miRNA
and un-transfected groups (Figure 1D). In addition, 48 h after
transfection of antisense transcripts to reduce the levels of miR-203
(anti-miR-203), Hakai protein levels were higher in the scrambled
Ctrl miRNA and un-transfected cells (Figure 1E), again in the
absence of changes in Hakai mRNA levels (Figure 1F), suggesting
that miR-203 influences Hakai mRNA translation rather than its
degradation. The effect of miR-203 upon Hakai levels was specific,
as reduction or overexpression of other miRNAs that were not
predicted to target Hakai mRNA, such as miR-21, did not
influence Hakai protein levels (Figure S2). Finally, the effect of the
transfected pre-miR-203 and anti-miR-203 in HeLa cells was also
slightly seen on Akt2 (Figure 1G), a previously described target for
miR-203 in bladder cancer [31,32].
The levels of Hakai and miR-203 were monitored in other
cultured human epithelial cell lines (human lung adenocarcinoma
A549, and human embryonic kidney HEK293 cells). Transfection
of HEK293 and A549 cells with anti-miR-203 similarly elevated
Hakai levels, while pre-miR-203 lowered Hakai levels (Figure 2A
and 2B, respectively). Hakai and miR-203 expression levels were
also analyzed in SW480 and in SW620 colon cell lines (Figure 2C
and 2D), two cell lines established from a primary colon
adenocarcinoma and its lymph node metastasis, respectively. In
this limited analysis, higher protein Hakai levels (but not Hakai
mRNA levels) were detected in SW620 than SW480 (Figure 2C),
further supporting the role of Hakai in tumour progression and
malignancy in colorectal cancers. Finally, the detected higher
Hakai protein levels in SW620 correlated with reduced miR-203
levels, while low Hakai levels in SW480 correlated to an increased
miR-203 levels (Figure 2C and 2D). These data support the notion
that miR-203 could broadly contribute to reduce Hakai expres-
sion.
Hakai is a Direct Target of miR-203
To investigate whether miR-203 repressed Hakai expression
through the predicted target sites on the Hakai 39-UTR, we
studied the influence of miR-203 on EGFP reporter constructs
bearing the segments of the Hakai mRNA with the predicted mi-
203 sites (Figure 3A). Expression of the parent control EGFP
reporter (pEGFP) and the Hakai 39-UTR miR-203 site (pEGFP-
39UTR) was tested in cells transfected with either scrambled Ctrl
miRNA or pre-miR-203. By Western blot analysis (Figure 3B),
miR-203 overexpression had no influence on EGFP expression
from pEGFP, while it reduced EGFP levels expressed from
pEGFP-39UTR (down to <10% of the levels seen in the
scrambled Ctrl miRNA group, quantification shown in
Figure 3C). These findings were verified by fluorescence micros-
copy (Figure 3D), where EGFP fluorescence was markedly and
selectively reduced after overexpression of pre-miR-203 in cells
transfected with pEGFP-39UTR. Taken together, these results
indicate that the 39UTR of Hakai mRNA contains sequences
through which miR-203 directly represses Hakai expression levels.
miR-203 Mediates Changes in Cell Proliferation through
its Influence on Hakai Levels
Since it was previously described that Hakai could influence cell
proliferation in an E-cadherin-independent manner, we used
epithelial cells that did not express E-cadherin to further analyze
cell division (Figure S1) [30]. In HeLa cells, we studied the effect of
reducing and elevating miR-203 on cell proliferation, by
measuring cell numbers 48 h after transfection. Pre-mir-203-
transfected HeLa cells, which express low levels of Hakai protein
(Figure 1 and 2), showed reduced cell numbers compared to
scrambled Ctrl miRNA population, while transfection of anti-
miR-203 increased Hakai protein levels (Figure 1 and 2), and cell
numbers (Figure 4A). Measurement of BrdU incorporation further
confirmed that cell proliferation was lower in anti-mir-203
transfected cells while it increases in pre-miR-203-transfected cells
miR-203/Hakai Regulates Cell Proliferation
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Figure 1. miR-203 modulates Hakai levels in HeLa cells. A, schematic representation of Hakai mRNA depicting two predicted miR-203 target
sites within the Hakai 39UTR. Alignment of consensus sequences of Hakai mRNA with miR-203; top strand, Hakai sequence; bottom strand, miR-203. B,
miR-203 levels measured by RT-qPCR after 48 h of untransfected HeLa cells, transfection with scrambled control miRNA (Ctrl) or the precursor miR-
203 (Pre-miR-203); U6 snRNA levels was used as control to monitor loading differences. C, levels of Hakai mRNA normalized to control HPRT mRNA
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were measured 48 h after transfecting HeLa cells with the indicated miRNAs. D, the effect of the indicated transfected miR-203 on Hakai levels in
HeLa cells were tested in HeLa whole-cell lysates by Western blotting (Top) and quantified by densitometry (Bottom), using Hakai antibody and a-
tubulin as loading control for normalization. E, the levels of Hakai and loading control a-tubulin were tested in whole-cell lysates by Western blotting
48 h after transfecting HeLa cells with the anti-miR-203 or scrambled control miRNA. F, the levels of Hakai mRNA 48 h after transfection of HeLa cells
with the anti-miR-203, or scrambled control miRNAs (each normalized to HPRT levels), were analyzed by RT-qPCR. G, western blotting analysis (Top)
and quantification by densitometry (Bottom) of AKT2 levels in HeLa cells expressing either pre-miR-203 or anti-miR-203, processed as described in D.
Western blotting signals were quantified by densitometry and shown in 1D. Values in B–D and F–G are the means 6 SEM from three independent
experiments. Statistical analyses indicate the significant difference in the indicated transfected miRNAs with respect to transfected scrambled control
(Ctrl) miRNA (*p,0.05, **p,0.01, ***p,0.001). The western blotting data are representative of three experiments.
doi:10.1371/journal.pone.0052568.g001
Figure 2. Influence of miR-203 on Hakai levels in several cell lines. A, the effect of modulating miR-203 levels in 293 cells was studied as
described in 1D and 1E; Western blot analysis (left panel) and quantification by densitometry (right panel). B, the effect of modulating miR-203 levels
in A549 cells was studied as described 1D and 1E. Western blot analysis (left panel) and quantification by densitometry (right panel). C, endogenous
Hakai expression levels in human colorectal cell lines (SW480 and SW620), as assessed by western blotting (upper panel) and by RT-qPCR (lower
panel) analysis. D, endogenous miR-203 levels in human colorectal cell lines (SW480 and SW620) by RT-qPCR (lower panel). Values (A–D) are the
means 6 SEM from three independent experiments. Significant differences in the indicated transfected miRNA with respect to transfected scrambled
control (Ctrl) miRNA for A–B, and the between SW480 and SW620 cell lines for C–D are indicated (*p,0.05, **p,0.01, ***p,0.001, n = 3). The western
blotting data are representative of three independent experiments.
doi:10.1371/journal.pone.0052568.g002
miR-203/Hakai Regulates Cell Proliferation
PLOS ONE | www.plosone.org 5 December 2012 | Volume 7 | Issue 12 | e52568
(Figure 4B). Other cell types were previously shown to be affected
similarly following modulation of miR-203 levels [32–35]. In
addition, flow cytometry analysis of cell cycle distribution further
revealed that pre-miR-203-transfected population had the smallest
S and G2/M phases and the largest G1 phase, while anti-miR-
203-transfected cells had the largest proportion of S-phase and
G2/M compartments (Figure 4C and 4D). Together with the
changes in DNA replication and cell cycle distribution profiles,
these results indicate that the miR-203 affected cell proliferation.
To examine if the effects of miR-203 on cell proliferation were
dependent on changes in Hakai abundance, we studied the effect
of knocking down Hakai on the proliferation rate of cultured
epithelial cells. Hakai protein were potently repressed following
transfection of two different Hakai-specific small interference
(si)RNA oligos (Figure 5A), an intervention that significantly
decreased BrdU incorporation (Figure 5B). Importantly, the anti-
miR-203-triggered increase in cell numbers was specifically
dependent on the presence of Hakai, as concomitant Hakai
silencing by siRNA in cells transfected with anti-miR-203
completely prevented the anti-miR-203-elicited proliferation, as
shown by BrdU incorporation analyses and by counting cell
numbers using hemocytometer (Figure 5C and 5D). As shown in
Figure 5E, the increase in Hakai protein triggered by anti-miR-
203 was abolished in cells co-transfected with siRNA-Hakai and
anti-miR-203. Moreover, ectopically expressed pEGFP-Hakai,
lacking its 39UTR, was cotransfected together with the pre-miR-
203, anti-miR-203 and scrambled control miRNA. Exogenous
Hakai protein levels were not affected by the presence of either of
two transfected miRNAs compared to scrambled control miRNA
(Figure S3), in keeping with the notion that the effect was
specifically dependent on the 39UTR of Hakai. Taken together,
our data support the view that miR-203 lowers cell proliferation at
least in part by reducing Hakai protein levels.
miR-203 and Hakai Expression in Tumour and the
Adjacent Healthy Colon Tissues
Given our earlier observations that Hakai levels were higher
in human colon cancer tissues [14], we extended this analysis to
19 pairs of human tumour and non-tumour colon samples.
Hakai abundance was markedly higher in tumour samples
compared to adjacent healthy colon tissues, as shown in a
representative image Figure 6A. The scoring result of the
Figure 3. miR-203 influence on Hakai reporter construct. A, schematic of EGFP reporter constructs bearing either no Hakai mRNA sequences
(pEGFP) or miR-203 target sites on the Hakai 39-UTR (pEGFP-39UTR). B, 48 h after cotransfection of the plasmids with scrambled control miRNA or Pre-
miR-203, the level of EGFP expressed was analyzed by Western blotting. C, quantification of panel B showing the effect of scrambled Ctrl miRNA or
pre-miR-203 on pEGFP and pEGFP-39UTR. Significant differences in EGFP expression from pEGFP-39UTR cotransfected with scrambled control miRNA
(Ctrl) and pEGFP-39UTR cotransfected with pre-miR-203 are indicated (***p,0.001). Western blotting data are the means 6 SEM from three
independent experiments.
doi:10.1371/journal.pone.0052568.g003
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Figure 4. Influence of miR-203 on cell proliferation. A, 48 h after transfection of HeLa cells with the miRNAs shown, cell numbers were
measured using a hemocytometer and represented as percentage of cells relative to the scrambled Ctrl miRNA group. B, measurement of BrdU
incorporation by 48 h after transfection of HeLa cells with the indicated miRNAs. The data in panels A, and B are the means 6 SEM from three
experiments. Significant differences in cell number (A) and BrdU incorporation (B) in the indicated transfected miRNA compared to transfected
scrambled (Ctrl) miRNA are indicated (*p,0.05, **p,0.01). C, forty-eight h after transfection with scrambled Ctrl miRNA, Anti-miR-203, or Pre-miR-
203, HeLa cells were subjected to FACS analysis. D, the relative G1, S, and G2/M compartments shown in C were calculated and represented in left
panel, and total cell numbers in every stage cell cycle compartment were included in the right panel. Data (C and D) are representative of three
independent experiments.
doi:10.1371/journal.pone.0052568.g004
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quantification of the intensity signal mean per area in healthy
and its paired tumour samples is shown in Figure S4.
Quantitative image analysis of immunohistochemical staining
revealed that tumour samples were significantly more intensely
stained for Hakai than its paired healthy samples, by Mann-
Whitney U test (*** = p,0.001, n = 19).
To study if miR-203 levels correlated inversely with Hakai
expression levels, we assessed miR-203 abundance by in situ
hybridization in four paired samples (Figure 6B). miR-203 shows
an attenuated expression in three of colon tumour tissues
compared to normal colon tissues and no differences were
detected in the other case analysed (data not shown) or when
using control U6 probe (Figure 6B, middle panel). Taken together,
these results suggest that reduced miR-203 levels in cancer tissues
could contribute to the up-regulation of Hakai levels. Our findings
support the notion that miR-203 function as a tumour suppressor
[35,36].
Discussion
In this study, we describe the repression of Hakai expression by
miR-203. Our findings indicate that miR-203 mainly reduces Hakai
protein levels, with only a slight effect on Hakai mRNA levels,
Figure 5. Influence of miR-203-regulated Hakai on cell proliferation. A, levels of Hakai and loading control a-tubulin were tested in whole-
cell lysates by Western blotting 48 h after transfecting HeLa cells with two different siRNAs oligos for Hakai relative to the scrambled Ctrl small RNA
group. B, 48 h after transfection of HeLa cells with the indicated siRNA oligos, cell numbers were measured by BrdU incorporation assay and
represented as percentage of cells. C, measurement of BrdU incorporation 48 h after transfection of HeLa cells with the indicated small RNAs. D,
measurement of cell number by hemocytometer after 48 h of transfection of HeLa cells with the indicated small RNAs. E, forty-eight h after
transfecting HeLa cells with the indicated small RNAs, Hakai and a-tubulin levels were measured by Western blot analysis. Western blotting data are
representative of three independent experiments. The data in panels B–D are the means 6 SEM from three experiments. Significant differences in
BrdU incorporation (B and C) and in cell number (D), compared to the transfected scrambled (Ctrl) small RNA are indicated (*p,0.05, **p,0.01).
doi:10.1371/journal.pone.0052568.g005
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suggesting that miR-203 controls Hakai translation, in keeping with
the mechanisms of miRNA-mediated repression of translation
[24,37]. Gene silencing by miRNA may occur by mRNA
degradation and/or repression of translation. The fate of the target
mRNA appears to be decided by the extent of base-pairing to the
miRNA. If there is a complete or near-perfect complementation
between the miRNA and target mRNA sequence, Ago2 can cleave
the mRNA and lead to direct mRNA degradation. On the other
hand, the presence of multiple, partially complementary sites in the
target mRNA will preferentially inhibit protein translation without
strongly affecting mRNA levels. However, this distinction is still
controversial, as even in the latter situation, miRNAs can strongly
decrease mRNA levels [20,38]. Ectopic reporters containing the
39UTR of Hakai protein showed that miR-203 elicited its repressive
influence at least in part through the Hakai 39UTR, which contains
two miR-203 in silico predicted sites (Figure 3A). We have used
TargetScan to predict miRNA targets based in seed sequence
conservation [38,39]. The degree of conservation of the binding site
is determined by the number of species with the same sequence and/
or by the phylogenetic distance between the species sharing the same
sequence. miR-203 belongs to miRNA families poorly conserved
among mammals or vertebrates. Two predicted targets sites are
Figure 6. Hakai and miR-203 expression in colon tissues. A, immunohistochemical analysis of Hakai protein expression in normal colon versus
colon cancer tissues. Differences between tumour samples compared to its paired healthy tissues are statistically significant (***p,0.001, n = 19). B, in
situ hybridization (ISH) for miR-203 (upper panel) and U6 snRNA (as control probe, middle panel) expression in colon cancer tissues compared to
normal colon tissue. Haematoxylin and eosin (H&E)-stained section (lower panel) was included to identify tumour area. Scale bar, 200 mm.
doi:10.1371/journal.pone.0052568.g006
miR-203/Hakai Regulates Cell Proliferation
PLOS ONE | www.plosone.org 9 December 2012 | Volume 7 | Issue 12 | e52568
found into the first five-hundred pair bases of the 39UTR of Hakai
mRNA, the region most likely to bear miRNA regulatory sites. By
Targetscan search (version release 5.1), the type of predicted sites for
miR-203 was 7mer-1A (a match to positions 2–7 of the mature
miRNA, the seed sequence, followed by an ‘A’). The negative score
of the site-type contribution is associated with a more favourable site
(for both sites the site type contribution is 20.074) [29], and the
position contributions are 20.032 for the site closest to the coding
region, and 20.008 for the second one, indicating that the first one is
associated to a more favourable binding site for regulation. By
searching for Hakai in other data base such as Tarbase 6.0 [40],
miR-26b-5p miRNA was found to associate to Hakai, although this
association was only described as a result of a high-throughput
microarray screening, and the functional role of this interaction is
still unknown [41]. In conclusion, up to date, miR-203 is the first
validated miRNA to influence Hakai protein levels.
Other mRNA targets have been previously described for miR-
203. For instance, miR-203 reduces p63 in skin differentiation
[42,43], and Akt2, Src, c-jun, survivin and bcl-w in bladder cancer
[33,34,36,44]. In addition, in prostate cancer, CKAP2, LASP1,
BIRC5, WASF1, ASAP1 and RUNX2 mRNAs were recently
identified as new miR-203 targets, suggesting that miR-203 could
be a new prognostic marker and a therapeutic target in metastasis
of prostate cancer [45].
The antiproliferative function of miRNA-203 was reported a
few years ago [46], but the complete set of targets have not been
identified, still an obstacle to understand miR-203 function in
cellular proliferation is the lack of well established validated targets
for specific type of cancer tissues. Our results have identified Hakai
as a critical effector of miR-203 actions on cell proliferation
(Figure 4 and 5). Supporting this point, the increased cell
proliferation seen after lowering miR-203 was strongly dependent
on the presence of Hakai, since Hakai silencing abolished the
proliferative phenotype (Figure 5C and 5D). miR-203 represses
the expression of other proliferative proteins in epithelial tissues,
such as survivin or bcl-w [33,36], so Hakai may function as one of
several protein coordinately regulated by miR-203 in order to
modulate cell proliferation. Apart from the validated miR-203
targets, there are numerous predicted miR-203 targets waiting for
validation; they include mRNAs encoding proteins implicated in
the pathways MAPK, Wnt, Notch, or IRS, which may also affect
cell proliferation. Therefore, the regulation of Hakai by miR-203,
at least, partially contributes to the regulation of cell proliferation.
In this work, we have used epithelial cells that do not express E-
cadherin in order to better study the effect of Hakai on cell
proliferation. This situation recapitulates the events that occur at
early stages of tumour progression. Indeed, Hakai is also detected
in tissues that do not express E-cadherin, such in the endoderm
epithelia or visceral mesoderm in Drosophila, or in human spleen
and skeletal muscle [7,13]. Moreover, Hakai can affect cell
proliferation in an E-cadherin-independent manner, suggesting
that it may be considered an oncogenic factor [7,13–15].
Furthermore, Hakai was proposed as a correpresor of estrogen
receptor alpha (ERa) in breast cancer cells [12], which is
according to previously reported ubiquitin-ligases that function
as transcriptional regulators [47,48].
The implication of miR-203 in different malignancies, such as
prostate or bladder cancers, was extensively studied in the past
[33,45]. miR-203 was also reported to be epigenetically silenced in
hematopoietic malignancies and hepatocellular carcinomas [34,35].
Here, we investigated its role in colon cancer tissues. Given that
Hakai was found up-regulated in human colon adenocarcinomas
[6,14], we extended our study by analyzing miR-203 expression by
in situ hybridization. We confirmed that Hakai abundance was
markedly higher in 17 tumour samples compared with adjacent
healthy colon tissues out of 19 pairs analyzed (Figure 6A and Figure
S4). By in situ hybridization, miR-203 presented lower levels of miR-
203 in 3 healthy samples compared to colon cancer from 4 pairs
analyzed, supporting the inverse correlation between Hakai
expression and miR-203 levels. These findings agree with the
hypothesis that miR-203 could help to maintain low levels of Hakai
in normal tissues, and that reduced miR-203 levels in colon cancer
tissues could contribute to maintain elevated Hakai levels. In light of
the influence of miR-203 on Hakai, future studies to test whether
miR-203 expression is broadly reduced in cancer are warranted. In
light of our results and the tumour suppressive function described for
miR-203 in other cancer types [32–35], we propose that miR-203
could be a potentially useful prognostic marker and a therapeutic
target in colon cancer.
Supporting Information
Figure S1 E-cadherin expression in the indicated epi-
thelial cell lines. Western blot analysis was carried to detect E-
cadherin; a-tubulin signals were assessed as loading control.
(EPS)
Figure S2 Analysis of a microRNA that is not predicted
to interact with Hakai mRNA. A, effect of the indicated
transfected pre-miR-21, anti-miR-21 or scrambled Ctrl miRNA
on Hakai levels tested in HeLa whole-cell lysates. Analysis was
carried out by Western blotting using Hakai antibody and a-
tubulin antibody as loading control. The western blotting data are
representative of three independent experiments. B, Quantifica-
tion by densitometry of the Western blotting signals. Values are
the means 6 SEM from three independent experiments. Student’s
T-test analyses indicate no significantly difference relative to
scrambled (Ctrl.) miRNA (p.0.25, n = 3).
(EPS)
Figure S3 Influence of the indicated miRNAs on pEGFP-
Hakai constructs. Forty-eight h after cotransfection of HeLa
cells with pEGFP-Hakai construct together with Pre-miR-203,
Anti-miR-203 or scrambled Ctrl miRNA, the levels of GFP and a-
tubulin (loading control) were measured by Western blot analysis
by using anti-GFP and anti-a-tubulin antibodies. Western blotting
data are representative of two independent experiments.
(EPS)
Figure S4 Quantification of Hakai immunohistochemi-
cal staining. Values are the means 6 S.E.M of the staining
intensity signal scoring per area. Calibration and quantification of
the images were performed with AnalySISD 5.0 software. Mann-
Whitney U test analyses show statistical differences in tumour
samples respect to paired healthy samples (***p,0.001, n = 19).
(EPS)
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